2019
|
|

Abstract: Aims To determine the incidence and severity of self‐reported hypoglycaemia in a primary care population with type 2 diabetes. The study also aimed to compare incidence by treatment regimen. Materials and methods A prospective observational study in 17 centres throughout the UK was conducted. Recruitment was based on treatment regimen (metformin alone, sulphonylurea‐, insulin‐ or incretin‐based therapy). Participants were asked to keep a blood glucose diary and self‐report hypoglycaemia episodes [non‐severe (s… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
0
14
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
4

Relationship

3
1

Authors

Journals

0
14
0
Order By: Relevance
“…Generalizations for the efficacy and safety of sulfonylureas as a class should, therefore, be avoided [64]. Additionally, despite previous data, a recent prospective study showed no increased risk of severe hypoglycaemia with sulfonylureas [65].…”
Section: Hypoglycaemia Weight Gain and Other Major Adverse Eventsmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 100,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Generalizations for the efficacy and safety of sulfonylureas as a class should, therefore, be avoided [64]. Additionally, despite previous data, a recent prospective study showed no increased risk of severe hypoglycaemia with sulfonylureas [65].…”
Section: Hypoglycaemia Weight Gain and Other Major Adverse Eventsmentioning
“…Based on the data from randomised trials, at least 232 patients would need to be treated with a sulfonylurea to cause one severe hypoglycaemic event (number needed to harm [NNH]), and the NNH for gliclazide MR specifically is 333 [ 41 , 42 , 54 56 ]. The low risk of symptomatic hypoglycaemia is supported by data from a prospective observational study of primary care T2DM patients in the UK [ 58 ]. This study showed a risk of hypoglycaemia (blood glucose < 3.0 mmol/L) of 0.12 per person-year with sulfonylureas, similar to the rate with incretin-based therapy (0.04 per person-year) and much lower than the rate with insulin (1.03 per person-year) [ 58 ].…”
Section: Place Of Sulfonylureas In Current Treatment Guidelinesmentioning
“…Clinical stratification . Hypoglycaemia risk is three‐times higher in patients on insulin secretagogues (sulphonylurea) and five‐times higher for those on insulin 44 …”
Section: Impaired Awareness Of Hypoglycaemiamentioning
“…Two types of anti‐diabetic agents are associated with hypoglycaemia—insulin secretagogues (ie, sulphonylureas) and insulin. As shown in Table 2, intensive treatment mainly with supplemental treatment with insulin and SU (ACCORD, ADVANCE, and VADT) shows that the risk of hypoglycaemic events are about 2‐ to 3‐fold higher than compared to standard treatment compared to newer glucose‐lowering agents 44, 109 . Within the last decade newer anti‐diabetic drugs have been developed and marketed with minimal if any risk of hypoglycaemia when used as monotherapy.…”
Section: Newer Anti‐diabetic Drugs and Risk Of Hypoglycaemiamentioning